Identification of amino acid sequences in fibrinogen γ-chain and tenascin C C-terminal domains critical for binding to integrin α(v)β3

Kenji Yokoyama, Harold P. Erickson, Yasuo Ikeda, Yoshikazu Takada

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Integrin α(v)β3 recognizes fibrinogen γ and α(E) chain C-terminal domains (γC and α(E)C) but does not require the γC dodecapeptide sequence HHLGGAKQAGDV400-411 for binding to γC. We have localized the α(v)β3 binding sites in γC using γC-derived synthetic peptides. We found that two peptides GWTVFQKRLDGSV190-202 and GVYYQGGTYSKAS346-358 block the α(v)β3 binding to γC or α(E)C, block the a{v)β3-mediated clot retraction, and induce the ligand-induced binding site 2 (LIBS2) epitope in a{v)β3. Neither peptide affects fibrinogen binding to α(IIb)β3. Scrambled or inverted peptides were not effective. These results suggest that the two γC-derived peptides directly interact with α(v)β3 and specifically block a{v)β3-γC or α(E)C interaction. The two sequences are located next to each other in the γC crystal structure, although they are separate in the primary structure. Asp-199, Ser-201, Gln-350, Thr-353, Lys- 356, Ala-357, and Ser-358 residues are exposed to the surface. This suggests that the two sequences are part of α(v)β3 binding sites in fibrinogen γC domain. We also found that tenascin C C-terminal fibrinogen-like domain specifically binds to α(v)β3. Notably, a peptide WYRNCHRVNLMGRYGDNHSQGVNWFHWKG from this domain that includes the sequence corresponding to γC GVYYQGGTYSKAS346-358 specifically binds to α(v)β3, suggesting that fibrinogen and tenascin C C-terminal domains interact with α(v)β3 in a similar manner.

Original languageEnglish
Pages (from-to)16891-16898
Number of pages8
JournalJournal of Biological Chemistry
Volume275
Issue number22
DOIs
Publication statusPublished - Jun 2 2000
Externally publishedYes

Fingerprint

Tenascin
Integrins
Fibrinogen
Amino Acid Sequence
Amino Acids
Peptides
Binding Sites
Clot Retraction
Epitopes
Ligands
Crystal structure

ASJC Scopus subject areas

  • Biochemistry

Cite this

Identification of amino acid sequences in fibrinogen γ-chain and tenascin C C-terminal domains critical for binding to integrin α(v)β3. / Yokoyama, Kenji; Erickson, Harold P.; Ikeda, Yasuo; Takada, Yoshikazu.

In: Journal of Biological Chemistry, Vol. 275, No. 22, 02.06.2000, p. 16891-16898.

Research output: Contribution to journalArticle

Yokoyama, Kenji ; Erickson, Harold P. ; Ikeda, Yasuo ; Takada, Yoshikazu. / Identification of amino acid sequences in fibrinogen γ-chain and tenascin C C-terminal domains critical for binding to integrin α(v)β3. In: Journal of Biological Chemistry. 2000 ; Vol. 275, No. 22. pp. 16891-16898.
@article{9e2ad3b8d2e94787ba36aed0506b84dc,
title = "Identification of amino acid sequences in fibrinogen γ-chain and tenascin C C-terminal domains critical for binding to integrin α(v)β3",
abstract = "Integrin α(v)β3 recognizes fibrinogen γ and α(E) chain C-terminal domains (γC and α(E)C) but does not require the γC dodecapeptide sequence HHLGGAKQAGDV400-411 for binding to γC. We have localized the α(v)β3 binding sites in γC using γC-derived synthetic peptides. We found that two peptides GWTVFQKRLDGSV190-202 and GVYYQGGTYSKAS346-358 block the α(v)β3 binding to γC or α(E)C, block the a{v)β3-mediated clot retraction, and induce the ligand-induced binding site 2 (LIBS2) epitope in a{v)β3. Neither peptide affects fibrinogen binding to α(IIb)β3. Scrambled or inverted peptides were not effective. These results suggest that the two γC-derived peptides directly interact with α(v)β3 and specifically block a{v)β3-γC or α(E)C interaction. The two sequences are located next to each other in the γC crystal structure, although they are separate in the primary structure. Asp-199, Ser-201, Gln-350, Thr-353, Lys- 356, Ala-357, and Ser-358 residues are exposed to the surface. This suggests that the two sequences are part of α(v)β3 binding sites in fibrinogen γC domain. We also found that tenascin C C-terminal fibrinogen-like domain specifically binds to α(v)β3. Notably, a peptide WYRNCHRVNLMGRYGDNHSQGVNWFHWKG from this domain that includes the sequence corresponding to γC GVYYQGGTYSKAS346-358 specifically binds to α(v)β3, suggesting that fibrinogen and tenascin C C-terminal domains interact with α(v)β3 in a similar manner.",
author = "Kenji Yokoyama and Erickson, {Harold P.} and Yasuo Ikeda and Yoshikazu Takada",
year = "2000",
month = "6",
day = "2",
doi = "10.1074/jbc.M000610200",
language = "English",
volume = "275",
pages = "16891--16898",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "22",

}

TY - JOUR

T1 - Identification of amino acid sequences in fibrinogen γ-chain and tenascin C C-terminal domains critical for binding to integrin α(v)β3

AU - Yokoyama, Kenji

AU - Erickson, Harold P.

AU - Ikeda, Yasuo

AU - Takada, Yoshikazu

PY - 2000/6/2

Y1 - 2000/6/2

N2 - Integrin α(v)β3 recognizes fibrinogen γ and α(E) chain C-terminal domains (γC and α(E)C) but does not require the γC dodecapeptide sequence HHLGGAKQAGDV400-411 for binding to γC. We have localized the α(v)β3 binding sites in γC using γC-derived synthetic peptides. We found that two peptides GWTVFQKRLDGSV190-202 and GVYYQGGTYSKAS346-358 block the α(v)β3 binding to γC or α(E)C, block the a{v)β3-mediated clot retraction, and induce the ligand-induced binding site 2 (LIBS2) epitope in a{v)β3. Neither peptide affects fibrinogen binding to α(IIb)β3. Scrambled or inverted peptides were not effective. These results suggest that the two γC-derived peptides directly interact with α(v)β3 and specifically block a{v)β3-γC or α(E)C interaction. The two sequences are located next to each other in the γC crystal structure, although they are separate in the primary structure. Asp-199, Ser-201, Gln-350, Thr-353, Lys- 356, Ala-357, and Ser-358 residues are exposed to the surface. This suggests that the two sequences are part of α(v)β3 binding sites in fibrinogen γC domain. We also found that tenascin C C-terminal fibrinogen-like domain specifically binds to α(v)β3. Notably, a peptide WYRNCHRVNLMGRYGDNHSQGVNWFHWKG from this domain that includes the sequence corresponding to γC GVYYQGGTYSKAS346-358 specifically binds to α(v)β3, suggesting that fibrinogen and tenascin C C-terminal domains interact with α(v)β3 in a similar manner.

AB - Integrin α(v)β3 recognizes fibrinogen γ and α(E) chain C-terminal domains (γC and α(E)C) but does not require the γC dodecapeptide sequence HHLGGAKQAGDV400-411 for binding to γC. We have localized the α(v)β3 binding sites in γC using γC-derived synthetic peptides. We found that two peptides GWTVFQKRLDGSV190-202 and GVYYQGGTYSKAS346-358 block the α(v)β3 binding to γC or α(E)C, block the a{v)β3-mediated clot retraction, and induce the ligand-induced binding site 2 (LIBS2) epitope in a{v)β3. Neither peptide affects fibrinogen binding to α(IIb)β3. Scrambled or inverted peptides were not effective. These results suggest that the two γC-derived peptides directly interact with α(v)β3 and specifically block a{v)β3-γC or α(E)C interaction. The two sequences are located next to each other in the γC crystal structure, although they are separate in the primary structure. Asp-199, Ser-201, Gln-350, Thr-353, Lys- 356, Ala-357, and Ser-358 residues are exposed to the surface. This suggests that the two sequences are part of α(v)β3 binding sites in fibrinogen γC domain. We also found that tenascin C C-terminal fibrinogen-like domain specifically binds to α(v)β3. Notably, a peptide WYRNCHRVNLMGRYGDNHSQGVNWFHWKG from this domain that includes the sequence corresponding to γC GVYYQGGTYSKAS346-358 specifically binds to α(v)β3, suggesting that fibrinogen and tenascin C C-terminal domains interact with α(v)β3 in a similar manner.

UR - http://www.scopus.com/inward/record.url?scp=0034595969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034595969&partnerID=8YFLogxK

U2 - 10.1074/jbc.M000610200

DO - 10.1074/jbc.M000610200

M3 - Article

VL - 275

SP - 16891

EP - 16898

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 22

ER -